Hepatitis C New Drugs Review
25.3K views | +0 today
Follow
 
Scooped by Krishan Maggon
onto Hepatitis C New Drugs Review
Scoop.it!

Telaprevir in HIV/HCV-coinfected patients: a new standard with a short half-life

Infectious Disease Medical Article: Telaprevir in HIV/HCV-coinfected patients: a new standard with a short half-life (Telaprevir in HIV/HCV-coinfected patients: a new standard with a short half-life: Future Virology
more...
No comment yet.
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
Scooped by Krishan Maggon
Scoop.it!

Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection

Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection | Hepatitis C New Drugs Review | Scoop.it
CTAC is Canada’s non-governmental organization led by and for people living with HIV and HIV/HCV co-infection, focusing on access to treatment. Since 1996, we have been working to secure and ensure equitable, affordable and timely access to treatment, care and support for people in Canada living with HIV and HIV/HCV co-infection. We work with community, public, private and not-for-profit leaders to inform research and public policy, and promote public awareness and discussion.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Home - STRIVING TOWARDS THE ELIMINATION OF HCV INFECTION - EASL Monothematic Conference

Home - STRIVING TOWARDS THE ELIMINATION OF HCV INFECTION - EASL Monothematic Conference | Hepatitis C New Drugs Review | Scoop.it
Topics to be covered Epidemiology Strategies for improved HCV testing and diagnosis Management of acute and chronic HCV infection HCV treatment and treatment failures The means to reach the WHO targets for HCV elimination The challenge of post-SVR management Key dates 06 Nov 2017 Abstract...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review | Hepatitis C New Drugs Review | Scoop.it
The burden of hepatitis C virus (HCV) infection is escalating among people who inject
drugs (PWID), yet testing and treatment remains suboptimal. The aim of this systematic
review was to evaluate the effectiveness of interventions to enhance HCV testing,
linkage to care, and treatment uptake among PWID.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Virus-Induced Autophagy and Host Innate Immune Response

Hepatitis C Virus-Induced Autophagy and Host Innate Immune Response | Hepatitis C New Drugs Review | Scoop.it
Autophagy is a catabolic process that is important for maintaining cellular homeostasis. This pathway in hepatocytes is stimulated and controlled by the hepatitis C virus (HCV)—upon infection—to promote its own replication. HCV induces autophagy indirectly and directly through different mechanisms and temporally controls the autophagic flux. This enables the virus to maximize its replication and attenuate the innate immune responses that it activates. In this review, we discuss the relationship between HCV and autophagy, and the crosstalk between HCV-induced autophagy and host innate immune responses.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Drug interactions in HIV-infected patients treated for hepatitis C

Drug interactions in HIV-infected patients treated for hepatitis C | Hepatitis C New Drugs Review | Scoop.it
(2017). Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opinion on Drug Metabolism & Toxicology: Vol. 13, No. 8, pp. 807-816. doi: 10.1080/17425255.2017.1351942
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States | Hepatitis C New Drugs Review | Scoop.it
(2017). Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. Journal of Medical Economics. Ahead of Print. doi: 10.1080/13696998.2017.1360313
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

PCPs Can Effectively Manage HCV Treatment with DAAs

PCPs Can Effectively Manage HCV Treatment with DAAs | Hepatitis C New Drugs Review | Scoop.it
In a 600-patient study, PCPs and NPs were shown to be just as effective as specialists in HCV treatment with direct-acting antivirals.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Shortening the duration of therapy for chronic hepatitis C infection

Shortening the duration of therapy for chronic hepatitis C infection | Hepatitis C New Drugs Review | Scoop.it
Combination direct-acting antiviral therapy of 8–24 weeks is highly effective for
the treatment of chronic hepatitis C infection. However, shortening the treatment
duration to less than 8 weeks could potentially reduce overall treatment costs and
improve adherence. Here we explore the arguments for and against the development of
short-duration regimens and existing data on treatment for 6 weeks or less among patients
with chronic hepatitis C virus genotype 1 infection. Additionally, we identify potential
predictors of response to short-course combination therapies with direct-acting antiviral
drugs that might be explored in future clinical trials.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use

Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use | Hepatitis C New Drugs Review | Scoop.it
T-cell therapy of chronic hepatitis B is a novel approach to restore antiviral T-cell immunity and cure the infection. We aimed at identifying T-cell receptors (TCR) with high functional avidity that have the potential to be used for adoptive T-cell therapy. To this end, we cloned HLA-A*02-restricted, hepatitis B virus (HBV)-specific T cells from patients with acute or resolved HBV infection. We isolated 11 envelope- or core-specific TCRs and evaluated them in comprehensive functional analyses. T cells were genetically modified by retroviral transduction to express HBV-specific TCRs. CD8+ as well as CD4+ T cells became effector T cells recognizing even picomolar concentrations of cognate peptide. TCR-transduced T cells were polyfunctional, secreting the cytokines interferon gamma, tumor necrosis factor alpha and interleukin-2, and effectively killed hepatoma cells replicating HBV. Notably, our collection of HBV-specific TCRs recognized peptides derived from HBV genotypes A, B, C and D presented on different HLA-A*02 subtypes common in areas with high HBV prevalence. When co-cultured with HBV-infected cells, TCR-transduced T cells rapidly reduced viral markers within two days. Our unique set of HBV-specific TCRs with different affinities represents an interesting tool for elucidating mechanisms of TCR-MHC interaction and dissecting specific anti-HBV mechanisms exerted by T cells. TCRs with high functional avidity might be suited to redirect T cells for adoptive T-cell therapy of chronic hepatitis B and HBV-induced hepatocellular carcinoma.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

AbbVie’s 8-Week Hepatitis C Drug to Rival Gilead’s Bestselling Therapies

AbbVie’s 8-Week Hepatitis C Drug to Rival Gilead’s Bestselling Therapies | Hepatitis C New Drugs Review | Scoop.it
The US Food and Drug Administration (FDA) has just approved AbbVie’s Mavyret (glecaprevir/pibrentasvir), the first treatment for hepatitis C to show a 98 percent cure rate in as little as eight weeks.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review | Hepatitis C New Drugs Review | Scoop.it
The burden of hepatitis C virus (HCV) infection is escalating among people who inject
drugs (PWID), yet testing and treatment remains suboptimal. The aim of this systematic
review was to evaluate the effectiveness of interventions to enhance HCV testing,
linkage to care, and treatment uptake among PWID.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Monitoring hepatitis C treatment uptake in Australia Issue 7, July 2017 | UNSW - The Kirby Institute for infection and immunity in society

Monitoring hepatitis C treatment uptake in Australia Issue 7, July 2017 | UNSW - The Kirby Institute for infection and immunity in society | Hepatitis C New Drugs Review | Scoop.it
Report type:  Research Reports Research program:  Year published:  2017 Download Monitoring hepatitis C treatment uptake in Australia Issue 7, July 2017 (508.65 KB) Description:  This report summarises data on the prescription and distribution of hepatitis C treatments and provides insight into...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes

AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes | Hepatitis C New Drugs Review | Scoop.it
MONTREAL, Aug. 17, 2017- AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead has directly cured 1.5 million HCV patients – just another 70 million to go, says Michael Mertens

Gilead has directly cured 1.5 million HCV patients – just another 70 million to go, says Michael Mertens | Hepatitis C New Drugs Review | Scoop.it
With the approval of Vosevi (sofosbuvir/velpatasvir/voxilaprevir) in the USA and Europe last month, US biotech giant Gilead Sciences has now brought to market f
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial | Hepatitis C New Drugs Review | Scoop.it
Our results show that 99% of patients treated with once-daily glecaprevir plus pibrentasvir
achieved a sustained virological response at 12 weeks. Furthermore, this drug regimen
had a favourable safety profile in previously treated or untreated patients with chronic
HCV genotype 1, 2, 4, 5, or 6 infection and compensated cirrhosis. These findings
could help simplify treatment algorithms and reduce treatment burden.
Krishan Maggon 's insight:
Lancet Published: 14 August 2017 
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial 

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments

Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments | Hepatitis C New Drugs Review | Scoop.it
In 2015, the Coalition to Eradicate Viral Hepatitis in Asia Pacific gathered leading
hepatitis experts from Bangladesh, India, Indonesia, Malaysia, Pakistan, the Philippines,
and Thailand to discuss common challenges to the burden posed by hepatitis B virus
(HBV) and hepatitis C virus (HCV), to learn from each other's experience, and identify
sustainable approaches. In this report, we summarise these discussions. Countries
differ in their policy responses to HBV and HCV; however, substantial systemic, cultural,
and financial barriers to achievement of elimination of these infections persist in
all countries.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cocrystal Pharma Hepatitis C picomolar inhibitor of NS5A

Cocrystal Pharma Hepatitis C picomolar inhibitor of NS5A | Hepatitis C New Drugs Review | Scoop.it
Developing a series of compounds that are potent non-nucleoside and nucleoside inhibitors of hepatitis C NS5B RNA dependent RNA polymerase, a replication enzyme that is essential to viral replication and is highly conserved between all hepatitis C genotypes. Therefore, inhibitors of this enzyme are likely to have multi- or pan-genotypic activity.

We are also developing compounds that inhibit hepatitis C NS5A and NS5B, two enzymes that are essential for viral replication. Cocrystal Pharma has identified a picomolar inhibitor of NS5A, another essential viral replication protein. Inhibitors of NS5A, in combination with nucleosides, have demonstrated excellent efficacy in treatment for hepatitis C in comparison with standard care. 

 Our compounds that target NS5B hepatitis C polymerase, NS5A and will be developed as a combination treatment. Such a combination treatment might have higher antiviral activity or a higher barrier to viral resistance than either treatment alone.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic

High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic | Hepatitis C New Drugs Review | Scoop.it
Though direct acting antivirals (DAAs) promise high cure rates, many providers and
payers remain concerned about successful treatment for people who use drugs (PWUD),
even among those engaged in opioid agonist treatment (OAT). The efficacy of DAAs among
PWUD in real-world settings is unclear.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Combating hepatitis B and C to reach elimination by 2030

Combating hepatitis B and C to reach elimination by 2030 | Hepatitis C New Drugs Review | Scoop.it
Advocacy brief on viral hepatitis: Combating hepatitis to reach elimination by 2030
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

London's calling: Let's eliminate Hepatitis C from group up

London's calling: Let's eliminate Hepatitis C from group up | Hepatitis C New Drugs Review | Scoop.it
MEDIA ROOM > LONDON'S CALLING: LET'S ELIMINATE HEPATITIS C FROM GROUP UP LONDON'S CALLING: LET'S ELIMINATE HEPATITIS C FROM GROUP UP Blenheim is a leading charity working across London to reduce the harm caused by drug and alcohol use to individuals and communities (blenheimcdp.org.uk).
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Treatment with PTEN-Long protein inhibits hepatitis C virus replication - ScienceDirect

Treatment with PTEN-Long protein inhibits hepatitis C virus replication - ScienceDirect | Hepatitis C New Drugs Review | Scoop.it
Publication date: November 2017
Source:Virology, Volume 511
Author(s): Qi Wu, Zhubing Li, Qiang Liu
Hepatitis C virus (HCV) infection is a confirmed risk factor for hepatocellular carcinoma (HCC). Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) possesses tumor suppression function that is frequently defective in HCC tumors. PTEN-Long, a translation isoform of PTEN, functions in a cell non-autonomous manner. In this study, we demonstrated that intracellular overexpression of PTEN-Long inhibits HCV replication. More importantly, we showed that treatment with extracellular PTEN-Long protein inhibits HCV replication in a dose-dependent manner. Furthermore, we showed that PTEN-Long interacts with HCV core protein and this interaction is required for HCV replication inhibition by PTEN-Long. In summary, we demonstrated, for the first time, that PTEN-Long protein, an isoform of the canonical PTEN and in the form of extracellular protein treatment, inhibits HCV replication. Our study offers an opportunity for developing additional anti-HCV agents.
Krishan Maggon 's insight:
Treatment with PTEN-Long protein inhibits hepatitis C virus replication . 

Virology Volume 511, November 2017, Pages 1-8
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Breakthrough immunotherapy for chronic hepatitis B virus infection

Breakthrough immunotherapy for chronic hepatitis B virus infection | Hepatitis C New Drugs Review | Scoop.it
This study, a collaborative effort between Duke-NUS, various prestigious Singapore & German institutions and Lion TCR, provides a potential solution to control the HBV infection
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

HCV Infection Treatment by Nonspecialist Providers (ASCEND) | Annals of Internal Medicine | American College of Physicians

HCV Infection Treatment by Nonspecialist Providers (ASCEND) | Annals of Internal Medicine | American College of Physicians | Hepatitis C New Drugs Review | Scoop.it
Abstract Background: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high rates of disease cure; however, not enough specialists currently are available to provide care.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Roche Receives FDA Approval for Viral Load Test Designed to Evaluate Hepatitis C Therapy | SelectScience

Roche Receives FDA Approval for Viral Load Test Designed to Evaluate Hepatitis C Therapy | SelectScience | Hepatitis C New Drugs Review | Scoop.it
Roche announced today that it has received approval from the US Food and Drug Administration (FDA) for a next-generation viral load test to be used in the management of patients with chronic hepatitis C virus (HCV) infection, which affects 200 million people globally. The COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 provides a novel dual-probe approach, for an extra layer of protection in detecting and quantifying the virus. The test is designed to accurately determine the amount of hepat
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Sub-Clinical Thyroid Disorders in Patients With Hepatitis C Before and After Conventional Treatment

Sub-Clinical Thyroid Disorders in Patients With Hepatitis C Before and After Conventional Treatment | Hepatitis C New Drugs Review | Scoop.it
Objective: Thyroid dysfunction represents one of the commonest endocrine manifestations of chronic hepatitis C
infection, exaggerated by interferon based treatment. Th..
more...
No comment yet.